Tenor Capital Management’s Biotech Acquisition Company Warrant BIOTW Stock Holding History

Tenor Capital Management’s Portfolio BIOTW Stock Details BIOTW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-140,290	Closed	-$8.96K	–	611
2022 Q4	$8.96K	Hold	140,290	–	–	﹤0.01%	430
2022 Q3	$8K	Hold	140,290	–	–	﹤0.01%	628
2022 Q2	$13K	Hold	140,290	–	–	﹤0.01%	654
2022 Q1	$34K	Hold	140,290	–	–	﹤0.01%	647
2021 Q4	$93K	Hold	140,290	–	–	﹤0.01%	563
2021 Q3	$93K	Hold	140,290	–	–	﹤0.01%	520
2021 Q2	$121K	Hold	140,290	–	–	﹤0.01%	550
2021 Q1	$84K	Buy	+140,290	New	+$98.9K	﹤0.01%	565

Tenor Capital Management's BIOTW Position: Q1 2023 in Review

Tenor Capital Management sold out of Biotech Acquisition Company Warrant (BIOTW) in Q1 2023, closing a stake of 140,290 shares — an estimated $8.96K sold.

Tenor Capital Management first reported a position in BIOTW in Q1 2021 and held it in 8 quarters. The position peaked at $121K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTW as of Q1 2023.

Tenor Capital Management reported no remaining Biotech Acquisition Company Warrant position as of Q1 2023 after selling out during the quarter.
Tenor Capital Management sold 140,290 Biotech Acquisition Company Warrant shares in Q1 2023, an estimated $8.96K.
Tenor Capital Management first reported a position in Biotech Acquisition Company Warrant in Q1 2021 and held it in 8 quarters.
Tenor Capital Management's Biotech Acquisition Company Warrant position peaked at $121K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Warrant as of Q1 2023.

Based on Tenor Capital Management's 13F filing for Q1 2023, filed 15 May 2023.